- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05694169
A Study of Participants With Chronic Kidney Disease Previously Treated With REACT
December 19, 2023 updated by: Prokidney
A Phase 1, Open-label, Supplemental Dosing Study of Participants With Chronic Kidney Disease Previously Treated With REACT (REGEN-015)
The purpose of this study is to evaluate the safety of supplemental REACT injections in participants with chronic kidney disease (CKD) who have previously received REACT treatment.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
A Phase 1, Open-label trial where up to 10 participants will enroll in the trial after parent REACT protocol EOS visit completion.
Participants may undergo a biopsy to manufacture REACT if additional biopsy tissue is required.
Participants will receive 2 REACT injections separated by 6 months.
All participants will be followed for 12 months post last supplemental REACT injection.
Study Type
Interventional
Enrollment (Estimated)
10
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Julie Lopez
- Phone Number: +1 919 788 3124
- Email: julie.lopez@iconplc.com
Study Contact Backup
- Name: Tierney Daigle
- Phone Number: +1 336-448-2843
- Email: tierney.daigle@prokidney.com
Study Locations
-
-
Idaho
-
Boise, Idaho, United States, 83642
- Recruiting
- Boise Kidney and Hypertension Institute
-
Contact:
- Arnold Silva, MD
- Phone Number: 208-846-8335
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- The participant has received REACT in a previous trial for treatment of chronic kidney disease and completed their parent protocol follow up period.
- The participant is male or female, 30 to 80 years of age on the date of informed consent.
- The participant has a documented clinical diagnosis of an eGFR greater than or equal to 14 and less than or equal to 50 mL/min/1.73m2, not requiring renal dialysis.
- The participant has stable blood pressure and is maintained on a stable antihypertensive medication regimen if treatment for hypertension is necessary.
Exclusion Criteria:
- The participant has a history of renal transplantation.
- The participant has received dialysis for more than 30 days.
- The participant has received any other investigational products after completion of REACT injections within 3 months of screening.
- The participant has a urinary albumin-to-creatinine ratio (UACR) of greater than 5,000 mg/g.
- The participant has hemoglobin levels less than 10 g/dL and is not responsive to the standard medical intervention for CKD-related anemia prior to screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Renal Autologous Cell Therapy (REACT)
Participants will receive 2 REACT injections separated by 6 months.
All participants will be followed for 12 months post last supplemental REACT injection.
|
Autologous selected renal cells (SRC)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Endpoints is as follows:
Time Frame: through 12 months after last supplemental injection
|
Procedure and investigational product-related treatment-emergent adverse events (TEAE) will be assessed via:
|
through 12 months after last supplemental injection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
First Secondary Endpoint
Time Frame: 12 months after the last supplemental injection
|
Percent of participants who have the same or reduced 5-year risk of end stage renal disease (ESRD)
|
12 months after the last supplemental injection
|
Second Secondary Endpoint
Time Frame: 12 months after the last supplemental injection
|
Percent of participants who have the same or reduced 2-year risk of ESRD
|
12 months after the last supplemental injection
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Study Director, Prokidney
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 11, 2023
Primary Completion (Estimated)
March 1, 2025
Study Completion (Estimated)
June 1, 2025
Study Registration Dates
First Submitted
December 27, 2022
First Submitted That Met QC Criteria
January 11, 2023
First Posted (Actual)
January 23, 2023
Study Record Updates
Last Update Posted (Actual)
December 21, 2023
Last Update Submitted That Met QC Criteria
December 19, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Urologic Diseases
- Endocrine System Diseases
- Disease Attributes
- Diabetes Complications
- Diabetes Mellitus
- Renal Insufficiency
- Chronic Disease
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Kidney Diseases
- Renal Insufficiency, Chronic
- Diabetic Nephropathies
Other Study ID Numbers
- REGEN-015
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Diseases
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsRecruitingChronic Kidney Diseases | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Chronic Renal Insufficiency | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Acute Kidney Insufficiency | Renal Failure, Acute | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney... and other conditionsUnited States
-
University of the State of Santa CatarinaUnknownKidney Diseases | Chronic Kidney Diseases | Hemodialysis | Chronic Renal Insufficiency | Renal Dialysis | Chronic Kidney Insufficiency | Chronic Renal DiseasesBrazil
-
Texas A&M UniversityWithdrawnChronic Kidney FailureUnited States
-
Lund UniversityBaxter Healthcare Corporation; Universidad de CórdobaCompletedEnd Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic DialysisArgentina
Clinical Trials on Renal Autologous Cell Therapy (REACT)
-
ProkidneyRecruitingChronic Kidney Diseases | Diabetic Kidney DiseaseUnited States
-
ProkidneyActive, not recruitingChronic Kidney Diseases | Type 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
ProkidneyCTI Clinical Trial and Consulting ServicesCompletedChronic Kidney Disease | Congenital Anomalies of Kidney and Urinary TractUnited States
-
ProkidneyCTI Clinical Trial and Consulting ServicesCompletedType 2 Diabetes Mellitus | Chronic Kidney DiseaseUnited States
-
ProkidneyIqvia Pty LtdNot yet recruitingChronic Kidney Diseases | Type 2 Diabetes Mellitus
-
ProkidneyCTI Clinical Trial and Consulting ServicesCompletedType 2 Diabetes Mellitus | Chronic Kidney DiseaseUnited States
-
ProkidneyPPD; Iqvia Pty LtdActive, not recruitingChronic Kidney Diseases | Type 2 Diabetes MellitusUnited States, United Kingdom, Taiwan, Australia, Canada
-
Dr. Grant M. PagdinRecruitingOsteoarthritisCanada
-
Hospitales NisaUniversitat Politècnica de ValènciaCompletedStroke | Hemiparesis | Chronic Stroke | Upper Limb InjurySpain
-
University of Alabama at BirminghamCompleted